RxDoctor Payments Data

Krista Verdi, PA

Physician Assistant · Center Valley, PANPI 1477534600

Payments from drug & device makers

$10,423in general payments, 2019–2025

Across 73 payments — averaging $142.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impel Pharmaceuticals LLC$4K
  • Lundbeck LLC$2K
  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$938
  • Pfizer$772
  • Biohaven Pharmaceutical Holding Company Ltd.$578
  • plus $390 from 3 others

What the payments were for

  • Consulting fees$1,35013%
  • Speaking & faculty fees$1,92018%
  • Travel & lodging$1,42614%
  • Food & beverage$5,71955%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,423 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$211,793
Medicare patients
95
Services billed
29,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant87$136,921
Emgality PenGalcanezumab-Gnlm163$125,162
Nurtec OdtRimegepant Sulfate50$101,161
QuliptaAtogepant50$75,594
Aimovig AutoinjectorErenumab-Aooe44$43,055
Ajovy AutoinjectorFremanezumab-Vfrm11$21,198
ReyvowLasmiditan Succinate19$15,717
Acetazolamide52$10,396
Topiramate ErTopiramate14$7,779
Acetazolamide ErAcetazolamide21$4,684
RizatriptanRizatriptan Benzoate141$2,201
Carbamazepine ErCarbamazepine17$1,960
Oxcarbazepine20$1,550
Topiramate107$1,189
Gabapentin93$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,713$212,515137 claims
PfizerNurtec Odt$772$101,16150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Center Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →